作者: I. Ilias , C. C. Chen , J. A. Carrasquillo , M. Whatley , A. Ling
DOI: 10.2967/JNUMED.108.052373
关键词:
摘要: We compared functional imaging modalities including positron emission tomography (PET) with 6-[18F]-fluorodopamine ([18F]-DA) against [123I]-metaiodobenzylguanidine ([123I]-MIBG) and somatostatin receptor scintigraphy (SRS) [111In]-pentetreotide (Octreoscan) in non-metastatic metastatic pheochromocytoma (PHEO). Methods: studied 25 men 28 women (mean age±SD: 44.2±14.2 years) biochemically-proven (n: 17) or 36) PHEO. Evaluation included anatomical computed (CT) and/or magnetic resonance (MRI) that at least two nuclear medicine modalities: [18F]-DA PET, [123I]-MIBG scintigraphy, SRS. Sensitivity of vs. was assessed on a per-patient per-region basis. Results For this available cohort, per patient basis, overall sensitivity (combined for PHEO) 90.2% 76.0% 22.0% On 75.4% 63.4% 64.0%